Focus: Structure Therapeutics is a public biotech company focused on oral small molecule drugs that deliver biologic-like activity and specificity, primarily targeting metabolic and infectious diseases. The company operates at a clinical-stage scale with a lean headcount and early-stage pipeline.
Profile data last refreshed 4h ago · AI intelligence enriched 1w ago
Hot — 69 jobs added in 30d
Net +61 (69 new, 8 removed). Aggressive expansion phase.
Suitable for early-career scientists or specialists willing to accept pre-revenue risk for equity upside and hands-on involvement in a focused, innovative platform.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Structure Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Structure Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles